

MYLAN LABORATORIES INC

Form 8-K

July 19, 2005

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **July 19, 2005**

MYLAN LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction of
Incorporation)

1-9114
(Commission File
Number)

25-1211621
(I.R.S. Employer
Identification No.)

**1500 Corporate Drive
Canonsburg, PA 15317**
(Address of principal executive offices)

(724) 514-1800
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition.

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EX-99.1

EX-99.2

Table of Contents

Item 2.02. Results of Operations and Financial Condition.

On July 19, 2005, Mylan Laboratories Inc., a Pennsylvania corporation (the Company), issued a press release reporting its financial results for the quarter ended June 30, 2005. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

The Company's unaudited condensed consolidated statements of earnings for the three months ended June 30, 2005 and June 30, 2004, and the unaudited condensed consolidated balance sheets at June 30, 2005 and March 31, 2005, were included in the Company's press release reporting its financial results for the quarter ended June 30, 2005, and are attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release of the registrant, dated July 19, 2005.
99.2	Unaudited condensed consolidated statements of earnings for the three months ended June 30, 2005 and June 30, 2004, and the unaudited condensed consolidated balance sheets at June 30, 2005 and March 31, 2005, of the registrant.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

Date: July 19, 2005

By: /s/ Edward J. Borkowski

Edward J. Borkowski
Chief Financial Officer

Table of Contents

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release of the registrant, dated July 19, 2005.
99.2	Unaudited condensed consolidated statements of earnings for the three months ended June 30, 2005 and June 30, 2004, and the unaudited condensed consolidated balance sheets at June 30, 2005 and March 31, 2005, of the registrant.